RU2016130684A - Гексагидрофуропирролы в качестве ингибиторов pde1 - Google Patents

Гексагидрофуропирролы в качестве ингибиторов pde1 Download PDF

Info

Publication number
RU2016130684A
RU2016130684A RU2016130684A RU2016130684A RU2016130684A RU 2016130684 A RU2016130684 A RU 2016130684A RU 2016130684 A RU2016130684 A RU 2016130684A RU 2016130684 A RU2016130684 A RU 2016130684A RU 2016130684 A RU2016130684 A RU 2016130684A
Authority
RU
Russia
Prior art keywords
compound
compound according
paragraphs
treatment
disease
Prior art date
Application number
RU2016130684A
Other languages
English (en)
Inventor
Ян Кехлер
Ларс Кихн Расмуссен
Мортен Ланггард
Original Assignee
Х. Лундбекк А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58698416&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2016130684(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Х. Лундбекк А/С filed Critical Х. Лундбекк А/С
Publication of RU2016130684A publication Critical patent/RU2016130684A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Claims (18)

1. Соединение со структурой:
Figure 00000001
где
R1 выбран из группы, состоящей из Н, F, С3-С6циклоалкила и C1-С4алкила.
R2-R11 выбраны из группы, состоящей из Н, С1-С3алкила, С3-С6циклоалкила, фтора, гидроксигруппы и C1-С6алкоксигруппы,
и фармацевтически приемлемые соли присоединения кислоты соединения (I), рацемические смеси соединения (I) или соответствующие энантиомер и/или оптический изомер соединения (I) и полиморфные формы соединения (I), а также таутомерные формы соединения (I).
2. Соединение по п. 1, где R1-R11 представляют собой Н.
3. Соединение по п. 1, где соединение представляет собой (3aS,6aS)-4-(7,8-диметоксихиназолин-4-ил)гексагидро-2Н-фуро[3,2-b]пиррол.
4. Соединение по п. 1, где соединение представляет собой (3aR,6aR)-4-(7,8-диметоксихиназолин-4-ил)гексагидро-2Н-фуро[3,2-b]пиррол.
5. Соединение по любому из пп. 1-4 для применения в качестве лекарственного средства.
6. Соединение согласно любому из пп. 1-4 для применения в лечении неврологического или психического расстройства.
7. Соединение согласно любому из пп. 1-4 для применения в лечении шизофрении.
8. Соединение согласно любому из пп. 1-4 для применения в лечении когнитивного нарушения при шизофрении.
9. Соединение согласно любому из пп. 1-4 для применения в лечении синдрома дефицита внимания с гиперактивностью (СДВГ).
10. Соединение согласно любому из пп. 1-4 для применения в лечении болезни Альцгеймера.
11. Соединение согласно любому из пп. 1-4 для применения в лечении болезни Паркинсона.
12. Соединение согласно любому из пп. 1-4 для применения в лечении болезни Хантингтона.
13. Фармацевтическая композиция, содержащая терапевтически эффективное количество соединения по п. 1 и один или несколько фармацевтически приемлемых носителей, разбавителей или наполнителей.
RU2016130684A 2014-02-07 2015-02-06 Гексагидрофуропирролы в качестве ингибиторов pde1 RU2016130684A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201400069 2014-02-07
DKPA201400069 2014-02-07
PCT/EP2015/052492 WO2015118097A1 (en) 2014-02-07 2015-02-06 Hexahydrofuropyrroles as pde1 inhibitors

Publications (1)

Publication Number Publication Date
RU2016130684A true RU2016130684A (ru) 2018-03-15

Family

ID=58698416

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016130684A RU2016130684A (ru) 2014-02-07 2015-02-06 Гексагидрофуропирролы в качестве ингибиторов pde1

Country Status (26)

Country Link
US (1) US9718832B2 (ru)
EP (1) EP3102584B1 (ru)
JP (1) JP6532880B2 (ru)
KR (1) KR20160115931A (ru)
CN (1) CN106414459B (ru)
AP (1) AP2016009344A0 (ru)
AR (1) AR099300A1 (ru)
AU (1) AU2015214214A1 (ru)
CA (1) CA2935470A1 (ru)
CL (1) CL2016001959A1 (ru)
CR (1) CR20160322A (ru)
DO (1) DOP2016000179A (ru)
EA (1) EA201691335A1 (ru)
EC (1) ECSP16071574A (ru)
ES (1) ES2711085T3 (ru)
GE (1) GEP201706795B (ru)
HK (1) HK1232214A1 (ru)
IL (1) IL246718A0 (ru)
MA (1) MA39230B1 (ru)
MX (1) MX2016010168A (ru)
PE (1) PE20161071A1 (ru)
PH (1) PH12016501495A1 (ru)
RU (1) RU2016130684A (ru)
SG (1) SG11201606445YA (ru)
TW (1) TW201611834A (ru)
WO (1) WO2015118097A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2776359T3 (es) * 2014-04-04 2020-07-30 H Lundbeck As Quinazolin-thf-aminas halogenadas como inhibidores de PDE1
CN110337437B (zh) 2016-12-28 2023-02-03 达特神经科学有限公司 作为pde2抑制剂的取代的吡唑并嘧啶酮化合物
KR20200108419A (ko) 2017-11-27 2020-09-18 다트 뉴로사이언스, 엘엘씨 Pde1 억제제로서의 치환된 푸라노피리미딘 화합물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060183763A1 (en) * 2004-12-31 2006-08-17 Pfizer Inc Novel pyrrolidyl derivatives of heteroaromatic compounds
CN101495476A (zh) 2006-07-10 2009-07-29 H.隆德贝克有限公司 6,7-二烷氧基喹唑啉、6,7-二烷氧基酞嗪和6,7-二烷氧基异喹啉的(3-芳基-哌嗪-1-基)、(2-芳基-吗啉-4-基)和(2-芳基-硫代吗啉-4-基)衍生物
WO2009078932A1 (en) * 2007-12-14 2009-06-25 Merck & Co., Inc. 3,4-substituted pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease

Also Published As

Publication number Publication date
MX2016010168A (es) 2016-10-07
WO2015118097A1 (en) 2015-08-13
CA2935470A1 (en) 2015-08-13
AP2016009344A0 (en) 2016-07-31
CL2016001959A1 (es) 2017-02-24
TW201611834A (en) 2016-04-01
ES2711085T3 (es) 2019-04-30
PE20161071A1 (es) 2016-10-30
AU2015214214A1 (en) 2016-07-14
HK1232214A1 (zh) 2018-01-05
EP3102584B1 (en) 2019-01-16
JP6532880B2 (ja) 2019-06-19
EP3102584A1 (en) 2016-12-14
MA39230B1 (fr) 2018-04-30
PH12016501495A1 (en) 2017-02-06
GEP201706795B (en) 2017-12-11
CN106414459A (zh) 2017-02-15
US20160347759A1 (en) 2016-12-01
DOP2016000179A (es) 2016-09-30
KR20160115931A (ko) 2016-10-06
AR099300A1 (es) 2016-07-13
ECSP16071574A (es) 2017-02-24
US9718832B2 (en) 2017-08-01
EA201691335A1 (ru) 2016-12-30
CN106414459B (zh) 2018-08-03
MA39230A1 (fr) 2017-07-31
CR20160322A (es) 2016-09-16
JP2017505328A (ja) 2017-02-16
SG11201606445YA (en) 2016-09-29
IL246718A0 (en) 2016-08-31

Similar Documents

Publication Publication Date Title
CL2018000036A1 (es) Derivados etinilo
MX2015015893A (es) 2-fenilimidazo[1,2-a]pirimidinas como agentes formadores de imagen.
PE20180021A1 (es) Derivados de sobetiroma
AR083358A1 (es) Compuestos de furo[3,2-d]pirimidina
AR096640A1 (es) Derivados de indolin-2-ona o pirrolo-piridin / pirimidin-2-ona
AR085219A1 (es) 6-cicloalquil-pirazolopirimidinonas para el tratamiento de trastornos del snc
EA201592146A1 (ru) Гетероароматические соединения и их применение в качестве лигандов к дофаминовым d1-рецепторам
EA201170962A1 (ru) Препарат разагилина с отсроченным высвобождением действующего вещества
AR099640A1 (es) Derivados de pirrolopiridina o pirazolopiridina
EA201071298A1 (ru) Соединение 3-аминокарбазола, фармацевтическая композиция, его содержащая, и способ их получения
EA201590520A1 (ru) Фармацевтическая композиция с покрытием, содержащая регорафениб
PH12016501100B1 (en) Ethynyl-imidazolin-2,4-dione derivatives as mglur4 modulators
EA201391341A1 (ru) Производные гетероциклических аминов
PE20141553A1 (es) Compuestos de triazolopiridina como inhibidores de la ped10a
RU2016130684A (ru) Гексагидрофуропирролы в качестве ингибиторов pde1
EA201691831A1 (ru) Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов
HRP20200369T1 (hr) Halogenirani kvinazolin-thf-amini kao inhibitori pde1
AR106588A1 (es) Derivados de indolin-2-ona para el tratamiento de enfermedades del snc
RU2016125315A (ru) Хиназолин-thf-амины в качестве ингибиторов pde1
EA201400120A1 (ru) Кристаллический (1r,4r)-6'-фтор-n,n-диметил-4-фенил-4',9'-дигидро-3'н-спиро[циклогексан-1,1'-пирано[3,4,в]индол]-4-амин
IL311208A (en) History of 2-amino-5,5-dimethylhexanoic acid as sortilin modulators for use in the treatment of diseases of the central nervous system
BR112016017816A8 (pt) derivados de etinila, seus usos, e composição farmacêutica
CO2018013824A2 (es) Derivados de etinilo
PH12016500605A1 (en) Pyrido[4,3-b]pyrazine-2-carboxamides as neurogenic agents for the treatment of neurodegenerative disorders
MY185216A (en) Piperazino[1,2-a]indol-ones and [1, 4]diazepino[1,2-a]indol-1-one

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20180207